RT Journal Article
T1 Translational pancreatic cancer research: A comparative study on patient-derived xenograft models.
A1 Rubio-Manzanares Dorado, Mercedes
A1 Marín Gómez, Luis Miguel
A1 Aparicio Sánchez, Daniel
A1 Pereira Arenas, Sheila
A1 Praena-Fernández, Juan Manuel
A1 Borrero Martín, Juan Jose
A1 Farfán López, Francisco
A1 Gómez Bravo, Miguel Ángel
A1 Muntané Relat, Jordi
A1 Padillo Ruiz, Javier
K1 Animal model
K1 Immunohistological analysis
K1 Nude mice
K1 Pancreatic cancer
K1 Patient-derived xenograft
AB To assess the viability of orthotopic and heterotopic patient-derived pancreatic cancer xenografts implanted into nude mice. This study presents a prospective experimental analytical follow-up of the development of tumours in mice upon implantation of human pancreatic adenocarcinoma samples. Specimens were obtained surgically from patients with a pathological diagnosis of pancreatic adenocarcinoma. Tumour samples from pancreatic cancer patients were transplanted into nude mice in three different locations (intraperitoneal, subcutaneous and pancreatic). Histological analysis (haematoxylin-eosin and Masson's trichrome staining) and immunohistochemical assessment of apoptosis (TUNEL), proliferation (Ki-67), angiogenesis (CD31) and fibrogenesis (α-SMA) were performed. When a tumour xenograft reached the target size, it was re-implanted in a new nude mouse. Three sequential tumour xenograft generations were generated (F1, F2 and F3). The overall tumour engraftment rate was 61.1%. The subcutaneous model was most effective in terms of tissue growth (69.9%), followed by intraperitoneal (57.6%) and pancreatic (55%) models. Tumour development was faster in the subcutaneous model (17.7 ± 2.6 wk) compared with the pancreatic (23.1 ± 2.3 wk) and intraperitoneal (25.0 ± 2.7 wk) models (P = 0.064). There was a progressive increase in the tumour engraftment rate over successive generations for all three models (F1 28.1% vs F2 71.4% vs F3 80.9%, P  In our experience, the faster development and greatest number of viable xenografts could make the subcutaneous model the best option for experimentation in pancreatic cancer.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12166
UL http://hdl.handle.net/10668/12166
LA en
DS RISalud
RD Apr 12, 2025